Rational approaches to resistance: Using saquinavir

AIDS, Supplement

Volumn 10, Issue 1, 1996, Pages

  Boucher, Charles ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cross resistance; HIV protease inhibitors; Resistance; Saquinavir

Indexed keywords

PROTEINASE INHIBITOR; SAQUINAVIR;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; CROSS RESISTANCE; DRUG RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; VIRUS REPLICATION;

ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; GENOTYPE; HIV; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HUMANS; POINT MUTATION; SAQUINAVIR;

EID: 0029806127     PISSN: 13502840     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. Kitchen VS, Skinner C, Ariyoshi K, et al.: Safely and activity of saquinavir in HIV infection. Lancet 1995, 345:952-955.
2. Shapiro JM, Winters MA, Kozal MJ, et al.: Saquinavir monotherapy trial: prolonged suppression of viral load and resistance mutations with higher dosage. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Franscisco, September 1995, 8 [abstract LB-5].
3. Vella S, Lazzarin A, Carosi G, et al.: A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection. Antiviral Ther 1996, 1:129-140.
4. Collier AC, Coombs RW, Schoenfeld DA, et al.: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996, 334:1011-1017.
5. Lalezari J, Haubrich R, Burger HU, et al.: Improved survival and decreased progression of HIV in patients treated with saquinavir (Invirase™,SQV) plus HIVID (zalcitabine, ddC). XI International Conference on AIDS. Vancouver, July 1996 [abstract LB.B.6033].
6. Jacobsen H, Hanggi M, Ott M, et al.: In vivo resistance to a human immunodeficiency virus type 1 protease inhibitor: mutations, kinetics and frequencies. J Infect Dis 1996, 173:1379-1387.
7. Tisdale M, Myers RE, Maschera B, et al.: Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother, 1995, 39:1704-1710.
8. Markowitz M, Mo H, Kempf DJ, et al.: Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol 1995, 69:701-706.
9. Partaledis JA, Yamaguchi K, Tisdale M, et al.: In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J Virol 1995, 69:5228-5235.
10. Roberts NA: Drug-resistance patterns of saquinavir and other HIV protease inhibitors. AIDS 1995, 9 (suppl 1):S27-S32.
11. Mellors JW, Larder BA, Schinazi RF: Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance. Int Antiviral News 1995, 3:8-13.
12. Condra JH, Schleif WA, Blahy OM, et al.: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374:569-571.
13. Race E, Gilbert SM, Tomlinson PW, et al.: Long term treatment with saquinavir does not lead to a significant reduction in sensitivity to MK-639. XI International Conference on AIDS. Vancouver, July 1996 [abstract 2792].
14. Maschera B, Tisdale M, Darby G, Mayer R, Thai G, Blair ED: In vitro growth characteristics of HIV-1 variants with reduced sensitivity to saquinavir explain the appearance of L90M escape mutant in vivo [abstract 85]. Antiviral Ther 1996, 1 (suppl 1):53-54.
15. Gao Q, Stewart K, Park C, et al.: Specific mutations in HIV-1 protease that confer diminished susceptibility to ABT-538 . 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 1995 [abstract 1282].
16. Molla A, Korneyeva M, Gao Q, et al.: Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996, 2:760-766.